Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEWED: Long-Term Follow-Up of Opicinumab in Acute Optic Neuritis
NCT02657915Phase 2Completed
- Sponsor
- Biogen
- Start
- Mar 2016
- Primary completion
- Jan 2017
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of opicinumab in optic neuritis (ON), sponsored by Biogen. Started Mar 2016; status: completed.
02
Drugs
opicinumab
03
Conditions
optic neuritis (ON)
Beyond the preview
Go deeper on NCT02657915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02657915.